+1 877 705 1914• 24 / 7
HIPAA Compliant
ISO 27001 Certified

Actively Recruiting

Phase 2
Age: 1Day - 4Years
All Genders
Healthy Volunteers
ID05654467

Phase 2 Study of a New Oral Type 3 Polio Vaccine Assessing Safety and Immune Response in Healthy Young Children, Infants, and Newborns in Panama

Led by PATH · Updated on 2026-05-11

1532

Participants Needed

3

Research Sites

N/A

Total Duration

AI-Summary

What This Trial Is About

Researchers are evaluating a new oral polio type 3 vaccine called nOPV3 in healthy young children, infants, and newborns. This phase 2, randomized, observer-blind study aims to assess the safety, immune response, virus shedding, and potential neurovirulence of nOPV3 compared to the Sabin monovalent type 3 vaccine mOPV3. The study will enroll 192 young children aged 1 to under 5 years, 860 infants around 6 weeks old, and 480 neonates at birth plus 3 days. Participants will be grouped by age and receive different doses of nOPV3 or mOPV3 vaccines. Young children will receive two doses 28 days apart. Infants will first get an inactivated poliomyelitis vaccine IPV dose, then two doses of nOPV3 or mOPV3, followed by a challenge dose of mOPV3. Neonates will receive two doses of either nOPV3 or mOPV3. Dose levels will be escalated across groups, with progress dependent on safety data from prior adult and pediatric cohorts. Throughout the study, researchers will monitor serious and mild side effects, immune response through blood tests, virus shedding in stool samples, and genetic stability of the vaccine virus using specialized tests. Participants will have multiple visits for vaccinations, assessments, and sample collections over approximately 18 months. Safety and immune responses will be carefully tracked to understand the vaccines effects in these age groups.

CONDITIONS

Brief Title

Study of a Novel Type 3 Oral Poliomyelitis Vaccine in Panama

Research Team

X

Xavier Saez-Llorens, MD

Not the Right Trial for You?

Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.

Already have an account? Log in here